SCHEMBL5337611

SCHEMBL5337611

COc1cc(C#N)c(NC(=O)Oc2ccccc2)cc1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.54
POLB P06746 1/20 0.51
ALDH1A1 P00352 7/20 0.48
GAA P10253 3/20 0.48
KDM4E B2RXH2 2/20 0.48
HPGD P15428 2/20 0.48
GLA P06280 1/20 0.48
ATM Q13315 1/20 0.48
HTT P42858 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
MAPT P10636 2/20 0.47
PPARG P37231 1/20 0.47
NCOA2 Q15596 1/20 0.47
NCOA1 Q15788 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.46
IMPDH2 P12268 1/20 0.45
TRPV1 Q8NER1 1/20 0.45
NPC1 O15118 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30644771 1.00 KMT2A (0.54) KMT2APOLBALDH1A1GAAKDM4E
SCHEMBL30542526 0.90 KMT2A (0.47) KMT2APOLBALDH1A1GAAKDM4E
SCHEMBL30542576 0.82 KMT2A (0.48) KMT2APOLBALDH1A1GAAKDM4E
SCHEMBL20267068 0.80 ALDH1A1 (0.55) KMT2AALDH1A1GAAKDM4EHPGD
SCHEMBL3894936 0.79 ALDH1A1 (0.53) KMT2AALDH1A1GAAKDM4EMAPT
SCHEMBL8103369 0.79 GAA (0.58) KMT2AALDH1A1GAAKDM4EHPGD
SCHEMBL30542559 0.78 POLB (0.47) KMT2APOLBALDH1A1GAAKDM4E
SCHEMBL1015519 0.77 MEN1 (0.47) KMT2APOLBALDH1A1GAAKDM4E
SCHEMBL11176848 0.77 KMT2A (0.72) KMT2APOLBALDH1A1GAAKDM4E
SCHEMBL7503515 0.77 ALDH1A1 (0.52) ALDH1A1GAAKDM4ENPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787783-B2 Heparanase inhibitors and use thereof Beta Therapeutics Pty Ltd (AU) 2023-10-17 US disclosed
US-11787783-B2 Heparanase inhibitors and use thereof Beta Therapeutics Pty Ltd (AU) 2023-10-17 US disclosed
US-20190345143-A1 HEPARANASE INHIBITORS AND USE THEREOF Beta Therapeutics Pty Ltd (AU) 2019-11-14 US disclosed
WO-2018107201-A1 HEPARANASE INHIBITORS AND USE THEREOF Beta Therapeutics Pty Ltd (AU) 2018-06-21 WO disclosed
US-7288537-B2 Azetidine derivatives as CCR-3 receptor antagonists NOVARTIS AG (CH) 2007-10-30 US disclosed
US-20050222118-A1 Azetidine derivatives as ccr-3 receptor antagonists NOVARTIS AG (CH) 2005-10-06 US disclosed
EP-1487435-A1 AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS Novartis AG (CH) 2004-12-22 EP disclosed
WO-2003077907-A1 AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222118-A1 Azetidine derivatives as ccr-3 receptor antagonists CCR3, CCR1, CCR9 KMT2A 3058/4885POLB 4233/4885ALDH1A1 2840/4885
US-20190345143-A1 HEPARANASE INHIBITORS AND USE THEREOF HPSE, HEXD, ENGASE KMT2A 3905/4885POLB 4333/4885ALDH1A1 1394/4885
US-11787783-B2 Heparanase inhibitors and use thereof HPSE, HEXD, ENGASE KMT2A 3905/4885POLB 4333/4885ALDH1A1 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.